NASDAQ:DRNADicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DRNA shares have increased by 15.9% and is now trading at $19.56. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) issued its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of $0.28 by $0.59. The biopharmaceutical company earned $34.03 million during the quarter, compared to analysts' expectations of $59.61 million. Dicerna Pharmaceuticals had a negative return on equity of 74.79% and a negative net margin of 213.04%. View Dicerna Pharmaceuticals' earnings history.

11 analysts have issued 1 year target prices for Dicerna Pharmaceuticals' shares. Their forecasts range from $25.00 to $50.00. On average, they anticipate Dicerna Pharmaceuticals' stock price to reach $34.20 in the next year. This suggests a possible upside of 74.8% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals.

News headlines about DRNA stock have trended very negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutDicerna Pharmaceuticals.

Dicerna Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 3,040,000 shares, a drop of 15.6% from the April 30th total of 3,600,000 shares. Based on an average daily trading volume, of 675,700 shares, the days-to-cover ratio is currently 4.5 days. Approximately 4.9% of the shares of the stock are sold short. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include United Therapeutics (UTHR), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), Emergent Biosolutions (EBS), Zai Lab (ZLAB), PPD (SDGR), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Evotec (EVTCY), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), Biohaven Pharmaceutical (BHVN) and GW Pharmaceuticals PLC- (GWPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Amarin (AMRN), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Array Biopharma (ARRY).

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.85%), Wellington Management Group LLP (5.24%), UBS Group AG (2.92%), Eagle Asset Management Inc. (2.36%), State Street Corp (2.28%) and Driehaus Capital Management LLC (1.37%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Brian K Halak, Dennis Langer, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View institutional ownership trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Federated Hermes Inc., Emerald Mutual Fund Advisers Trust, Morgan Stanley, JPMorgan Chase & Co., EAM Investors LLC, Squarepoint Ops LLC, and WINTON GROUP Ltd. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, and Peter Kolchinsky. View insider buying and selling activity for Dicerna Pharmaceuticals.

DRNA stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Invesco Ltd., AXA, Assenagon Asset Management S.A., Two Sigma Advisers LP, Schroder Investment Management Group, and Connor Clark & Lunn Investment Management Ltd.. View insider buying and selling activity for Dicerna Pharmaceuticals.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $19.56.

Dicerna Pharmaceuticals has a market capitalization of $1.45 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]